Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases
Rahul S. Dalal, Jordan C. Pruce, Jessica R. Allegretti
Abstract
Lay Summary In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients for up to 24 months.
Topics & Concepts
UstekinumabMedicineInflammatory bowel diseaseRetrospective cohort studyInflammatory Bowel DiseasesCrohn's diseaseInternal medicineGastroenterologyCohortCohort studyDiseaseAdalimumabInflammatory Bowel DiseaseImmunodeficiency and Autoimmune DisordersEosinophilic Esophagitis